Case Report: Dramatic Response to Crizotinib in a Patient With Non-Small Cell Lung Cancer Positive for a Novel Fusion

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Mar 3

PMID 35237515

Authors

Qing Ma

Lingping Kong

Diansheng Zhong

Affiliations

Soon will be listed here.

Abstract

It is imperative to know the status of oncogenic drivers in patients with non-small cell lung cancer (NSCLC). Compared with and fusion, fusion is relatively rare in NSCLC. In this case, we report the case of a female patient with NSCLC positive for a novel fusion. The patient achieved about a 5-month progression-free survival (PFS) after receiving crizotinib for unresectable right lung malignancies. To the best of our knowledge, this case provides the first clinical evidence that the novel fusion might be an actionable mutation in NSCLC.

Citing Articles

Remarkable response to capmatinib in a patient with intrahepatic cholangiocarcinoma harboring - fusion.

Ueta A, Yamada A, Yoshioka M, Kanai M, Muto M, Okita N Int Cancer Conf J. 2024; 13(3):199-203.

PMID: 38962049 PMC: 11217255. DOI: 10.1007/s13691-024-00664-8.

Dramatic response to crizotinib through MET phosphorylation inhibition in rare TFG-MET fusion advanced squamous cell lung cancer.

Cheng W, Xu T, Yang L, Yan N, Yang J, Fang S Oncologist. 2024; 30(1).

PMID: 38954846 PMC: 11783276. DOI: 10.1093/oncolo/oyae166.

A novel gene fusion variant in lung adenocarcinoma with prolonged response to tepotinib: a case report.

Dias E Silva D, Mambetsariev I, Fricke J, Babikian R, Dingal S, Mazdisnian F Transl Lung Cancer Res. 2024; 13(5):1163-1168.

PMID: 38854944 PMC: 11157375. DOI: 10.21037/tlcr-24-34.

Response to Savolitinib in a Patient with Advanced Poorly Differentiated Lung Carcinoma Positive for a Novel EML4-MET Gene Fusion.

Ouyang G, Shu P, Xue Y, Luo F, Li Y Onco Targets Ther. 2024; 17:79-84.

PMID: 38313385 PMC: 10838107. DOI: 10.2147/OTT.S442685.

MET alterations detection platforms and clinical implications in solid tumors: a comprehensive review of literature.

Yuan P, Xue X, Qiu T, Ying J Ther Adv Med Oncol. 2024; 16:17588359231221910.

PMID: 38249331 PMC: 10798113. DOI: 10.1177/17588359231221910.

References

Cui J . Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress. J Med Chem. 2013; 57(11):4427-53. DOI: 10.1021/jm401427c. View

Zou H, Li Q, Lee J, Arango M, McDonnell S, Yamazaki S . An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007; 67(9):4408-17. DOI: 10.1158/0008-5472.CAN-06-4443. View

Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G . Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012; 12(2):89-103. DOI: 10.1038/nrc3205. View

Yu C, Lee F . Multiple activities of Arl1 GTPase in the trans-Golgi network. J Cell Sci. 2017; 130(10):1691-1699. DOI: 10.1242/jcs.201319. View

Qi J, McTigue M, Rogers A, Lifshits E, Christensen J, Janne P . Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res. 2011; 71(3):1081-91. PMC: 3208270. DOI: 10.1158/0008-5472.CAN-10-1623. View

Nelson A, Schrock A, Pavlick D, Ali S, Atkinson E, Chachoua A . Novel SPECC1L-MET Fusion Detected in Circulating Tumor DNA in a Patient with Lung Adenocarcinoma following Treatment with Erlotinib and Osimertinib. J Thorac Oncol. 2019; 14(2):e27-e29. DOI: 10.1016/j.jtho.2018.10.160. View

Cui J, Tran-Dube M, Shen H, Nambu M, Kung P, Pairish M . Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem. 2011; 54(18):6342-63. DOI: 10.1021/jm2007613. View

Diamond J, Salgia R, Varella-Garcia M, Kanteti R, LoRusso P, Clark J . Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma. J Clin Oncol. 2013; 31(16):e254-8. PMC: 3661938. DOI: 10.1200/JCO.2012.46.4289. View

Zhu Y, Wang W, Song Z, Zhang Q, Xu C, Chen G . MET-UBE2H Fusion as a Novel Mechanism of Acquired EGFR Resistance in Lung Adenocarcinoma. J Thorac Oncol. 2018; 13(10):e202-e204. DOI: 10.1016/j.jtho.2018.05.009. View

10.

Cho J, Ku B, Sun J, Lee S, Ahn J, Park K . KIF5B-MET Gene Rearrangement with Robust Antitumor Activity in Response to Crizotinib in Lung Adenocarcinoma. J Thorac Oncol. 2017; 13(3):e29-e31. DOI: 10.1016/j.jtho.2017.10.014. View

11.

Pal K, Bandyopadhyay A, Zhou X, Xu Q, Marciano D, Brunzelle J . Structural Basis of TPR-Mediated Oligomerization and Activation of Oncogenic Fusion Kinases. Structure. 2017; 25(6):867-877.e3. PMC: 5507626. DOI: 10.1016/j.str.2017.04.015. View

12.

Seo J, Ju Y, Lee W, Shin J, Lee J, Bleazard T . The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res. 2012; 22(11):2109-19. PMC: 3483540. DOI: 10.1101/gr.145144.112. View

13.

Plenker D, Bertrand M, de Langen A, Riedel R, Lorenz C, Scheel A . Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients. Clin Cancer Res. 2017; 24(6):1337-1343. DOI: 10.1158/1078-0432.CCR-17-3001. View

14.

Zhu Y, Wang W, Xu C, Zhang Q, Du K, Chen G . Identification of a novel crizotinib-sensitive MET-ATXN7L1 gene fusion variant in lung adenocarcinoma by next generation sequencing. Ann Oncol. 2018; 29(12):2392-2393. DOI: 10.1093/annonc/mdy455. View

15.

Rodig S, Shapiro G . Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. Curr Opin Investig Drugs. 2010; 11(12):1477-90. View

16.

Paik P, Drilon A, Fan P, Yu H, Rekhtman N, Ginsberg M . Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov. 2015; 5(8):842-9. PMC: 4658654. DOI: 10.1158/2159-8290.CD-14-1467. View

17.

Davies K, Ng T, Estrada-Bernal A, Le A, Ennever P, Camidge D . Dramatic Response to Crizotinib in a Patient with Lung Cancer Positive for an Gene Fusion. JCO Precis Oncol. 2018; 2017(1). PMC: 5844276. DOI: 10.1200/PO.17.00117. View

18.

Luque-Cabal M, Garcia-Teijido P, Fernandez-Perez Y, Sanchez-Lorenzo L, Palacio-Vazquez I . Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It. Clin Med Insights Oncol. 2016; 10(Suppl 1):21-30. PMC: 4811269. DOI: 10.4137/CMO.S34537. View